IRVINE, CA – (Marketwired – September 26, 2016) – Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces that its President, Chief Executive Officer, and Co-Founder, Mr. Raymond C. Dabney, has accepted an invitation to speak at Harvard Medical School this November. Mr. Dabney will address speak at the Dana Farber/Harvard Cancer Center (DF/HCC), one of the largest cancer research centers in the world with more than 1,100 cancer researchers and over $600 million in cancer research funding. He will discuss CBIS’ drug development initiatives targeting a variety of cancers, within the context of a number of other disorders, such as autism spectrum disorders, asthma, as well as pain management.
“I am excited to have the opportunity to tell the CBIS story to a new audience at the Harvard Medical School. In discussing our work with the experts and thought-leaders at Harvard – as well as by learning more about the cutting-edge research being done at DF/HCC – we will be better positioned to continue our drug development program on effective treatments that will help the largest possible number of people in need,” said Mr. Dabney.
Mr. Dabney also agreed to participate in the Harvard Medical School’s Global Health Catalyst Summit in April 2017, and to serve as a Role Model Speaker to minorities and K-12 students beginning in early 2017. For the Global Health Catalyst Summit, Mr. Dabney will be one of the lead Diaspora keynote speakers and he will explore the use of cannabinoids in the management of acute and chronic diseases within the African Diaspora. Chronic diseases like cancer and heart diseases represent an ever growing burden of disease across Africa. Mr. Dabney has been a role model for many years and he will share with K-12 students, will motivate young leaders to develop integrated, sustainable and successful business enterprises. “I look forward to participating in these three, exciting programs at the Harvard Medical School over the next several months. Not only will I have the opportunity to share ideas with recognized experts and help inspire young leaders, but I will also have the opportunity to create visibility for the CBIS brand in a manner that will be mutually beneficial to the Harvard Medical School and CBIS,” said Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Cannabis Science, Inc.
Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)